Health and Healthcare

Amgen Nails Earnings, Guidance a Different Story

Amgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings came in up 30% at $1.82 per share, and revenue was up 13% to $5.01 billion. Thomson Reuters had estimates of $1.68 in earnings per share and $4.82 billion in revenue. Product sales were up 11% in the quarter.

Guidance for all of 2014 was put at $7.90 to $8.20 in earnings per share and $19.2 to $19.6 billion in revenue. Thomson Reuters had estimates of $8.18 in earnings per share and $19.58 billion in revenue.

Amgen now has 10 drug development programs with registration-enabling data expected by 2016. It also claims to have six biosimilars in development and has expanded presence in more than 75 countries.

Neulasta and Neupogen sales combined were up 8% for the quarter, and some select product sales growth was as follows: Enbrel up 3% (driven by price), Aranesp dropped 4% on lower unit demand, Sensipar/Mimpara sales increased 20% based on unit demand and price.

Amgen shares closed up 1.8% at $120.70, against a 52-week range of $39.24 to $84.40. The after-hours reaction had shares down only a few pennies initially.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.